Moderna announces data on flu, pandemic flu candidates at IDWeek 2025

Moderna (MRNA) announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations are as follows: Late-Breaking Oral Presentation: mRNA-1010, an mRNA-Based Influenza Vaccine, is Safe and Efficacious in Adults Aged greater than or equal to50 Years: The presented data show the relative vaccine efficacy of mRNA-1010 for the prevention of influenza compared to a licensed standard dose influenza vaccine. rVE was 26.6% in the overall study population, meeting the prespecified superiority criteria. Oral Presentation #220: Safety and Immunogenicity of mRNA-1018, a candidate vaccine for the prevention of H5N1 pandemic influenza, in healthy adults greater than or equal to18 years of age in a dose-ranging Phase 1/2 clinical study: The presented data show that across all dose levels, mRNA-1018 was well-tolerated with no safety concerns identified, and demonstrated rapid and persistent immune response. Three weeks after the second dose, the immune responses in 97.8% of participants were at or above levels considered protective from influenza.